Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CG001 injection in generalized myasthenia gravis
CTR20263476Phase 2Active
- Sponsor
- Kangjing Biomedical
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CG001 in myasthenia gravis (MG), sponsored by Kangjing Biomedical. Started Sep 2026; status: active.
02
Drugs
CG001
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20263476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263476.